Lite Strategy (formerly MEI Pharma) is a clinical-stage oncology company that has abandoned its pharmaceutical strategy and pivoted to holding Litecoin (LTC) as its primary reserve asset. The legacy pharma business centered on two cancer drug candidates — voruciclib, an oral CDK9 inhibitor for relapsed/refractory AML and B-cell malignancies, and zandelisib, an oral PI3Kδ inhibitor co-developed with Kyowa Kirin — neither of which was ever approved or commercialized. All clinical trials were halted by mid-2024, and the company is only conducting limited preclinical work on these assets. After failing to find viable out-licensing or M&A opportunities, the company raised $100M via a PIPE in mid-2025 and deployed the net proceeds into Litecoin, a decentralized cryptocurrency designed as a faster, more storage-efficient alternative to Bitcoin. Lite Strategy's new business model mirrors MicroStrategy's Bitcoin treasury approach, but applied to Litecoin: the company holds LTC as its primary asset, has an at-the-market equity agreement to potentially raise additional capital to buy more Litecoin, and is considering Litecoin mining operations. The company generates little to no operating revenue and has four employees. In September 2025, the company rebranded from MEI Pharma to Lite Strategy and changed its ticker to LITS.